These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15823760)

  • 1. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.
    Tripathy D; Body JJ; Bergström B
    Clin Ther; 2004 Dec; 26(12):1947-59. PubMed ID: 15823760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibandronate reduces skeletal morbidity in patients with breast cancer.
    Tripathy A D; Diel I; Body JJ
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):64-6. PubMed ID: 15490378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.
    Body JJ; Diel IJ; Lichinitzer M; Lazarev A; Pecherstorfer M; Bell R; Tripathy D; Bergstrom B
    Br J Cancer; 2004 Mar; 90(6):1133-7. PubMed ID: 15026791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibandronate: its role in metastatic breast cancer.
    Cameron D; Fallon M; Diel I
    Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
    Gordon DH
    Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.
    Tripathy D; Lichinitzer M; Lazarev A; MacLachlan SA; Apffelstaedt J; Budde M; Bergstrom B;
    Ann Oncol; 2004 May; 15(5):743-50. PubMed ID: 15111341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibandronate: efficacy in the treatment of metastatic bone disease.
    Diel IJ
    Future Oncol; 2005 Oct; 1(5):593-607. PubMed ID: 16556036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy.
    Pecherstorfer M; Diel IJ
    Support Care Cancer; 2004 Dec; 12(12):877-81. PubMed ID: 15372222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibandronate in metastatic bone pain.
    Heidenreich A; Ohlmann C; Body JJ
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):67-72. PubMed ID: 15490379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
    Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R
    Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of ibandronate in the daily oncological practice].
    Nagykálnai T
    Magy Onkol; 2006; 50(4):325-7. PubMed ID: 17216006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer.
    Heras P; Karagiannis S; Kritikos K; Hatzopoulos A; Mitsibounas D
    Eur J Cancer Care (Engl); 2007 Nov; 16(6):539-42. PubMed ID: 17944770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Support Care Cancer; 2005 Dec; 13(12):975-86. PubMed ID: 15871033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.
    Diel IJ; Body JJ; Lichinitser MR; Kreuser ED; Dornoff W; Gorbunova VA; Budde M; Bergström B;
    Eur J Cancer; 2004 Jul; 40(11):1704-12. PubMed ID: 15251160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature.
    Meattini I; Bruni A; Scotti V; Livi L; De Luca Cardillo C; Galardi A; Cipressi S; Biti G
    J Chemother; 2010 Feb; 22(1):58-62. PubMed ID: 20227995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.